???pagination.result.count???
Tonic Calcium-Activated Chloride Current Sustained by ATP Release and Highly Desensitizing Human P2X1 Receptors. , Limon A, Hagopian G, Reyes-Ruiz JM, Miledi R ., Neuroscience. July 15, 2020; 439 332-341.
Identification of aurintricarboxylic acid as a potent allosteric antagonist of P2X1 and P2X3 receptors. , Obrecht AS, Urban N, Schaefer M, Röse A, Kless A, Meents JE, Lampert A, Abdelrahman A, Müller CE, Schmalzing G, Hausmann R., Neuropharmacology. November 1, 2019; 158 107749.
A challenge finding P2X1 and P2X4 ligands. , Beswick P, Wahab B, Honey MA, Paradowski M, Jiang K, Lochner M, Murrell-Lagnado RD, Thompson AJ., Neuropharmacology. October 1, 2019; 157 107674.
Comparative Embryonic Spatio-Temporal Expression Profile Map of the Xenopus P2X Receptor Family. , Blanchard C, Boué-Grabot E, Massé K ., Front Cell Neurosci. January 1, 2019; 13 340.
Mapping the binding site of the P2X receptor antagonist PPADS reveals the importance of orthosteric site charge and the cysteine-rich head region. , Huo H, Fryatt AG, Farmer LK, Schmid R, Evans RJ., J Biol Chem. August 17, 2018; 293 (33): 12820-12831.
Two P2X1 receptor transcripts able to form functional channels are present in most human monocytes. , López-López C, Jaramillo-Polanco J, Portales-Pérez DP, Gómez-Coronado KS, Rodríguez-Meléndez JG, Cortés-García JD, Espinosa-Luna R, Montaño LM, Barajas-López C., Eur J Pharmacol. December 15, 2016; 793 82-88.
Mechanistic insights from resolving ligand-dependent kinetics of conformational changes at ATP-gated P2X1R ion channels. , Fryatt AG, Dayl S, Cullis PM, Schmid R, Evans RJ., Sci Rep. September 12, 2016; 6 32918.
Presynaptic P2X1-3 and α3-containing nicotinic receptors assemble into functionally interacting ion channels in the rat hippocampus. , Rodrigues RJ, Almeida T, Díaz-Hernández M, Marques JM, Franco R, Solsona C, Miras-Portugal MT, Ciruela F, Cunha RA., Neuropharmacology. June 1, 2016; 105 241-257.
Contribution of the Juxtatransmembrane Intracellular Regions to the Time Course and Permeation of ATP-gated P2X7 Receptor Ion Channels. , Allsopp RC, Evans RJ., J Biol Chem. June 5, 2015; 290 (23): 14556-66.
Use of chimeras, point mutants, and molecular modeling to map the antagonist-binding site of 4,4',4″,4‴-(carbonylbis-(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakisbenzene-1,3-disulfonic acid (NF449) at P2X1 receptors for ATP. , Farmer LK, Schmid R, Evans RJ., J Biol Chem. January 16, 2015; 290 (3): 1559-69.
Validation of Alexa-647-ATP as a powerful tool to study P2X receptor ligand binding and desensitization. , Bhargava Y, Nicke A, Rettinger J ., Biochem Biophys Res Commun. August 23, 2013; 438 (2): 295-300.
P2X receptor chimeras highlight roles of the amino terminus to partial agonist efficacy, the carboxyl terminus to recovery from desensitization, and independent regulation of channel transitions. , Allsopp RC, Farmer LK, Fryatt AG, Evans RJ., J Biol Chem. July 19, 2013; 288 (29): 21412-21421.
Gintonin, a ginseng-derived lysophosphatidic acid receptor ligand, potentiates ATP-gated P2X₁ receptor channel currents. , Choi SH, Kim HJ , Kim BR, Shin TJ, Hwang SH, Lee BH, Lee SM, Rhim H, Nah SY., Mol Cells. February 1, 2013; 35 (2): 142-50.
Mass spectrometry analysis of human P2X1 receptors; insight into phosphorylation, modelling and conformational changes. , Roberts JA, Bottrill AR, Mistry S, Evans RJ., J Neurochem. December 1, 2012; 123 (5): 725-35.
Involvement of the cysteine-rich head domain in activation and desensitization of the P2X1 receptor. , Lörinczi É, Bhargava Y, Marino SF, Taly A, Kaczmarek-Hájek K, Barrantes-Freer A, Dutertre S, Grutter T, Rettinger J , Nicke A., Proc Natl Acad Sci U S A. July 10, 2012; 109 (28): 11396-401.
P2X2 and P2X5 subunits define a new heteromeric receptor with P2X7-like properties. , Compan V, Ulmann L, Stelmashenko O, Chemin J, Chaumont S, Rassendren F., J Neurosci. March 21, 2012; 32 (12): 4284-96.
Agonist binding evokes extensive conformational changes in the extracellular domain of the ATP-gated human P2X1 receptor ion channel. , Roberts JA, Allsopp RC, El Ajouz S, Vial C, Schmid R, Young MT, Evans RJ., Proc Natl Acad Sci U S A. March 20, 2012; 109 (12): 4663-7.
Molecular basis of selective antagonism of the P2X1 receptor for ATP by NF449 and suramin: contribution of basic amino acids in the cysteine-rich loop. , El-Ajouz S, Ray D, Allsopp RC, Evans RJ., Br J Pharmacol. January 1, 2012; 165 (2): 390-400.
Cloning and functional analysis of P2X1b, a new variant in rat optic nerve that regulates the P2X1 receptor in a use-dependent manner. , Rangel-Yescas GE, Vazquez-Cuevas FG, Garay E, Arellano RO ., Acta Neurobiol Exp (Wars). January 1, 2012; 72 (1): 18-32.
Cloning and characterization of a P2X receptor expressed in the central nervous system of Lymnaea stagnalis. , Bavan S, Straub VA, Webb TE, Ennion SJ., PLoS One. January 1, 2012; 7 (11): e50487.
The intracellular amino terminus plays a dominant role in desensitization of ATP-gated P2X receptor ion channels. , Allsopp RC, Evans RJ., J Biol Chem. December 30, 2011; 286 (52): 44691-701.
Cysteine scanning mutagenesis (residues Glu52-Gly96) of the human P2X1 receptor for ATP: mapping agonist binding and channel gating. , Allsopp RC, El Ajouz S, Schmid R, Evans RJ., J Biol Chem. August 19, 2011; 286 (33): 29207-17.
Contribution of the intracellular C terminal domain to regulation of human P2X1 receptors for ATP by phorbol ester and Gq coupled mGlu(1α) receptors. , Wen H, Evans RJ., Eur J Pharmacol. March 5, 2011; 654 (2): 155-9.
Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor. , Baqi Y, Hausmann R, Rosefort C, Rettinger J , Schmalzing G, Müller CE., J Med Chem. February 10, 2011; 54 (3): 817-30.
Amino acid residues constituting the agonist binding site of the human P2X3 receptor. , Bodnar M, Wang H, Riedel T, Hintze S, Kato E, Fallah G, Gröger-Arndt H, Giniatullin R, Grohmann M, Hausmann R, Schmalzing G, Illes P, Rubini P., J Biol Chem. January 28, 2011; 286 (4): 2739-49.
Selective potentiation of homomeric P2X2 ionotropic ATP receptors by a fast non-genomic action of progesterone. , De Roo M, Boué-Grabot E, Schlichter R., Neuropharmacology. March 1, 2010; 58 (3): 569-77.
Contribution of the region Glu181 to Val200 of the extracellular loop of the human P2X1 receptor to agonist binding and gating revealed using cysteine scanning mutagenesis. , Roberts JA, Valente M, Allsopp RC, Watt D, Evans RJ., J Neurochem. May 1, 2009; 109 (4): 1042-52.
A P2X receptor from the tardigrade species Hypsibius dujardini with fast kinetics and sensitivity to zinc and copper. , Bavan S, Straub VA, Blaxter ML, Ennion SJ., BMC Evol Biol. January 20, 2009; 9 17.
Regions of the amino terminus of the P2X receptor required for modification by phorbol ester and mGluR1alpha receptors. , Wen H, Evans RJ., J Neurochem. January 1, 2009; 108 (2): 331-40.
Direct modulation of P2X1 receptor-channels by the lipid phosphatidylinositol 4,5-bisphosphate. , Bernier LP, Ase AR, Tong X, Hamel E, Blais D, Zhao Q, Logothetis DE, Séguéla P., Mol Pharmacol. September 1, 2008; 74 (3): 785-92.
Cysteine substitution mutagenesis and the effects of methanethiosulfonate reagents at P2X2 and P2X4 receptors support a core common mode of ATP action at P2X receptors. , Roberts JA, Digby HR, Kara M, El Ajouz S, Sutcliffe MJ, Evans RJ., J Biol Chem. July 18, 2008; 283 (29): 20126-36.
Lack of evidence for direct phosphorylation of recombinantly expressed P2X(2) and P2X (3) receptors by protein kinase C. , Franklin C, Braam U, Eisele T, Schmalzing G, Hausmann R., Purinergic Signal. September 1, 2007; 3 (4): 377-88.
Cysteine substitution mutants give structural insight and identify ATP binding and activation sites at P2X receptors. , Roberts JA, Evans RJ., J Neurosci. April 11, 2007; 27 (15): 4072-82.
Identification of an intersubunit cross-link between substituted cysteine residues located in the putative ATP binding site of the P2X1 receptor. , Marquez-Klaka B, Rettinger J , Bhargava Y, Eisele T, Nicke A., J Neurosci. February 7, 2007; 27 (6): 1456-66.
Contribution of P2X1 receptor intracellular basic residues to channel properties. , Vial C, Rigby R, Evans RJ., Biochem Biophys Res Commun. November 10, 2006; 350 (1): 244-8.
Contribution of conserved polar glutamine, asparagine and threonine residues and glycosylation to agonist action at human P2X1 receptors for ATP. , Roberts JA, Evans RJ., J Neurochem. February 1, 2006; 96 (3): 843-52.
Contribution of conserved glycine residues to ATP action at human P2X1 receptors: mutagenesis indicates that the glycine at position 250 is important for channel function. , Digby HR, Roberts JA, Sutcliffe MJ, Evans RJ., J Neurochem. December 1, 2005; 95 (6): 1746-54.
Potentiation of P2X1 ATP-gated currents by 5-hydroxytryptamine 2A receptors involves diacylglycerol-dependent kinases and intracellular calcium. , Ase AR, Raouf R, Bélanger D, Hamel E, Séguéla P., J Pharmacol Exp Ther. October 1, 2005; 315 (1): 144-54.
Regulatory interdependence of cloned epithelial Na+ channels and P2X receptors. , Wildman SS, Marks J, Churchill LJ, Peppiatt CM, Chraibi A, Shirley DG, Horisberger JD, King BF , Unwin RJ., J Am Soc Nephrol. September 1, 2005; 16 (9): 2586-97.
Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt]. , Hechler B, Magnenat S, Zighetti ML, Kassack MU, Ullmann H, Cazenave JP, Evans R, Cattaneo M, Gachet C., J Pharmacol Exp Ther. July 1, 2005; 314 (1): 232-43.
Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist. , Rettinger J , Braun K, Hochmann H, Kassack MU, Ullmann H, Nickel P, Schmalzing G, Lambrecht G., Neuropharmacology. March 1, 2005; 48 (3): 461-8.
Mutagenesis studies of conserved proline residues of human P2X receptors for ATP indicate that proline 272 contributes to channel function. , Roberts JA, Evans RJ., J Neurochem. March 1, 2005; 92 (5): 1256-64.
Biochemical and functional evidence for heteromeric assembly of P2X1 and P2X4 subunits. , Nicke A, Kerschensteiner D, Soto F., J Neurochem. February 1, 2005; 92 (4): 925-33.
Trimeric architecture of homomeric P2X2 and heteromeric P2X1+2 receptor subtypes. , Aschrafi A, Sadtler S, Niculescu C, Rettinger J , Schmalzing G., J Mol Biol. September 3, 2004; 342 (1): 333-43.
G-protein-coupled receptor regulation of P2X1 receptors does not involve direct channel phosphorylation. , Vial C, Tobin AB, Evans RJ., Biochem J. August 15, 2004; 382 (Pt 1): 101-10.
ATP binding at human P2X1 receptors. Contribution of aromatic and basic amino acids revealed using mutagenesis and partial agonists. , Roberts JA, Evans RJ., J Biol Chem. March 5, 2004; 279 (10): 9043-55.
Desensitization masks nanomolar potency of ATP for the P2X1 receptor. , Rettinger J , Schmalzing G., J Biol Chem. February 20, 2004; 279 (8): 6426-33.
Dissecting individual current components of co-expressed human P2X1 and P2X7 receptors. , Seyffert C, Schmalzing G, Markwardt F., Curr Top Med Chem. January 1, 2004; 4 (16): 1719-30.
NF449, a novel picomolar potency antagonist at human P2X1 receptors. , Hülsmann M, Nickel P, Kassack M, Schmalzing G, Lambrecht G, Markwardt F., Eur J Pharmacol. May 30, 2003; 470 (1-2): 1-7.
Activation and desensitization of the recombinant P2X1 receptor at nanomolar ATP concentrations. , Rettinger J , Schmalzing G., J Gen Physiol. May 1, 2003; 121 (5): 451-61.